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ABSTRACT
The objective of this study was to describe the time of onset and offset of bone mineral density (BMD) loss relative to the date of the final
menstrual period (FMP); the rate and amount of BMD decline during the 5 years before and the 5 years after the FMP; and the
independent associations between age at FMP, bodymass index (BMI), and race/ethnicity with rates of BMD loss during this time interval.
The sample included 242 African American, 384 white, 117 Chinese, and 119 Japanese women, pre- or early perimenopausal at baseline,
who had experienced their FMP and for whom an FMP date could be determined. Loess-smoothed curves showed that BMD loss began 1
year before the FMP and decelerated (but did not cease) 2 years after the FMP, at both the lumbar spine (LS) and femoral neck (FN) sites.
Piecewise, linear, mixed-effects regression models demonstrated that during the 10-year observation period, at each bone site, the rates
and cumulative amounts of bone loss were greatest from 1 year before through 2 years after the FMP, termed the transmenopause.
Postmenopausal loss rates, those occurring between 2 and 5 years after the FMP, were less than those observed during transmenopause.
Cumulative, 10-year LS BMD loss was 10.6%; 7.38% was lost during the transmenopause. Cumulative FN loss was 9.1%; 5.8% was lost
during the transmenopause. Greater BMI and African American heritage were related to slower loss rates, whereas the opposite was true
of Japanese and Chinese ancestry.  2012 American Society for Bone and Mineral Research.
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Introduction
Bone loss begins before the cessation of menses. Dual-energyX-ray absorptiometry (DXA) detects unequivocal decline in
bone mineral density during late perimenopause, when women
have experienced between 3 and 11 months of amenorrhea,
whereas little, if any, loss is seen during early perimenopause,
when menstrual cycles are irregular but there has not yet been a
gap of at least 3 months between periods.(1–3) Menstrually
defined menopause transition (MT) categories, which classify
stages of the menopause according to menstrual irregularity or
number of months of amenorrhea, are imprecise predictors of
when the final menstrual period (FMP) will occur. Women who
are in early or late perimenopause may be more or less proximal
to their FMP, and rates of bone mineral density (BMD) loss may
therefore differ within menstrually defined stages. Similary, the
time at which bone loss decelerates after the FMP cannot be
discriminated using menstrually classified MT stages.
Amore precise description of onset and offset of bone loss can
be obtained by modeling BMD change in relation to the FMP
date. Using this approach, two longitudinal studies of white
women found BMD loss accelerated about 2 years before the
FMP and slowed, but did not cease, about 2 years after it.(4,5)
However, sample sizes in these investigations were modest and
neither included minority women, which is an important
consideration because ethnic-specific patterns of bone loss
during the MT could contribute to the known ethnic variation in
fracture rates.(6–9)
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This analysis examines rates of BMD change in relation to the
observed date of the FMP, in contrast to menopause transition
stages, in a multiethnic cohort of African American, white,
Chinese, and Japanese midlife women. The objectives of this
study were to: 1) describe the timing of the onset and offset of
accelerated BMD loss in relation to FMP date; 2) quantify the rate
and amount of BMD decline at the lumbar spine (LS) and femoral
neck (FN) during the 5 years before and after the FMP; and 3)
assess whether body mass index, ethnic/racial origin, or age at
FMP influenced the rate of BMD loss.
Materials and Methods
Study sample
The Study of Women’s Health Across the Nation (SWAN) is a
multisite, community-based, longitudinal cohort study of the
MT.(10) Eligibility criteria were: age between 42 and 52 years,
intact uterus and at least one intact ovary, not currently using
hormone therapy, at least one menstrual period in the 3 months
before screening, and self-identification as a member of one
of five eligible ethnic groups. Participants were enrolled at
seven sites in the US: Boston, MA; Chicago, IL; Detroit, MI;
Pittsburgh, PA; Los Angeles, CA; Newark, NJ; and Oakland, CA
(N¼ 3302). All sites enrolled whites. Boston, Chicago, Detroit,
and Pittsburgh enrolled African Americans, and the remaining
three sites enrolled Japanese, Hispanic, and Chinese women,
respectively. The Chicago and Newark sites did not measure
BMD, leaving a potential of 2413 participants for the SWAN
bone-density cohort. Of these, 2335 were enrolled in the
bone cohort at baseline. The current analysis includes data
from baseline to follow-up visit 10; only bone cohort participants
who had a determinable natural (not surgical) FMP date were
eligible. Hormone therapy use and other pharmacological agents
that affect bone (ie, tamoxifen, raloxifene, GnRH agonists,
corticosteroids, or osteoporosis treatments) were exclusions,
applied at baseline. The inception cohort size was 862. Data
from women who initiated bone-active medicine were censored
at the time of first use. See Supplemental Fig. S1 for a flow
diagram of the sample derivation. Participants gave written
informed consent and sites obtained institutional review board
approval.
Outcomes
LS and FN BMD (g/cm2) were measured annually using Hologic
instruments (Hologic, Inc., Waltham, MA, USA). Three sites used
Hologic 4500A models throughout. Two sites upgraded from
2000 to 4500Amodels at follow-up visit 8. These sites scanned 40
women on both their old and new machines to develop cross-
calibration regression equations. A standard quality-control
program, conducted in collaboration with Synarc, Inc. (Newark,
CA, USA), included daily phantom measurements, 6-month
cross-calibration with a circulating anthropomorphic spine
standard, local site review of all scans, central review of scans
that met problem-flagging criteria, and central review of a 5%
random sample of scans. Short-term in vivo measurement
variability was 0.014 g/cm2 (1.4%) for the LS and 0.016 g/cm2
(2.2%) for the FN.
Primary predictor
The primary exposure, the number of months before or after the
FMP that the BMD was taken, was computed using the month
and year of the FMP and themonth and year of each annual BMD
assessment. FMP date was determined by annual, standardized
interview. FMP date was defined as the last menstrual bleeding
date reported during the visit immediately before the first visit
when the participant was classified as postmenopausal (had
12 months of amenorrhea).
Other predictors
Age (years), self-defined race/ethnicity (African American, white,
Chinese, Japanese), menstrual bleeding patterns, hormone
therapy use (yes/no, time-varying), use of any medication that
affects bone density (yes/no, time-varying) were obtained using
annual, standardized interviews. Menopause transition stages
(time-varying, based on reported annual bleeding patterns)
were defined as: premenopausal (regular menses, no change
from individual’s pattern), early perimenopausal (menses
within the last 3 months but less predictable than individual’s
pattern), late perimenopausal (at least 3 months but less than
12 consecutive months of amenorrhea), and postmenopausal
(12 or more months without menses). Weight (kilograms, time-
varying) and height (meters) were assessed annually, using
calibrated scales and stadiometers. Body mass index (BMI,
[weight in kilograms/(height in meters)2]) was calculated
annually.
Data analysis
Characteristics of bone cohort participants included and
excluded from analysis were compared using t tests (continuous
variables) and chi-squared tests (categorical variables). To
analyze change in BMD in relation to FMP date, we used a
staged approach, consisting of 1) nonparametric, loess-based
selection of the functional form of the BMD trajectory in relation
to FMP date, 2) piecewise linear regression to determine knot
placement for the parametric BMD trajectory, and 3) piecewise
linear regression with fixed knots to estimate BMD decline rates
during each phase of the trajectory. First, the loess method was
used on repeated annual LS or FN measurements; each
participant’s BMD was normalized to her baseline.(11)
In steps 2 and 3, we used mixed effects regression to fit
piecewise linear models to repeated measurements of baseline-
normalized LS or FN BMD (in separate models) as functions of
time before or after FMP, using linear splines with fixed knots at
FMP minus 1 year and FMP plus 2 years. To account for within-
woman correlation between repeated observations, we included
random effects for the intercept and 3 slopes (allowing the
intercept and slopes to vary from woman to woman). In step 2,
we tested model adequacy and appropriateness of knot
locations by running null models with only random effects
and no fixed effects. The fraction of within-woman variance
in BMD explained by the three-segment, piecewise-linear,
null model was 84.2% for LS BMD and 71.7% for FN BMD.
We evaluated knot selection by examining the change in
the explained proportion of within-woman variance (pseudo
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R-square) when the knots were varied around FMP minus 1 year
and FMP plus 2 years. The amount of explained variance was
unambiguously lessened by knot movement (in 6-month
intervals) away from FMP minus 1 year. However, the explained
fraction was unaltered by subtracting or adding 6 months to the
knot at FMP plus 2 years. We therefore chose FMP plus 2 years for
the knot placement because it represented the midpoint
(indicating gradual deceleration, in contrast to the fairly rapid
acceleration at FMP minus 1 year). The explained fraction of
within-woman variance also did not change when we used raw
(unnormalized) or log-transformed BMD instead of baseline-
normalized BMD. We present baseline-normalized BMD for ease
of interpretation: The regression slopes are equivalent to
percentage changes in BMD from baseline. Because we adjusted
the models for baseline BMD, individual differences in starting
BMD do not influence estimated percentages.
In the third step, we added age at FMP, race/ethnicity, and
baseline BMI to the mixed-effects piecewise models, as
fixed effects on the intercept and three slopes, to assess
how each influenced the rate of BMD decline during each
segment of the longitudinal, piecewise model. The BMD
trajectories were divided into three linear segments in
relation to FMP date (time 0): years 5 to 1 relative to the
FMP, termed pretransmenopause; years 1 to þ2 relative to the
FMP, termed transmenopause; and yearsþ2 toþ5 after the FMP,
termed postmenopause. We also modeled the effect of change
in BMI since baseline on BMD values at follow-up. Models were
adjusted for baseline BMD and clinical site. The effects of each
predictor on the slopes for each segment were combined to
obtain total effects on BMD decline during the 10-year period.
Results are expressed as means and 95% confidence intervals
(CI); 95% CIs that exclude 1 are considered statistically significant.
Analyses were conducted using SAS version 9.2 (SAS Institute,
Cary, NC, USA).
Results
The analytic sample consisted of 242 African American, 384
white, 117 Chinese, and 119 Japanese women. At baseline, mean
value of age was 46.7 years (standard deviation [SD] 2.6 years),
mean age at FMP was 51.6 (SD 2.4 years), and average bodymass
index was 27.4 kg/m2 (SD 7 kg/m2). The baseline percentages of
premenopausal and early perimenopausal women were 58%
and 41%, respectively; 16% were current smokers. These
characteristics were similar to those of the SWAN bone cohort
participants who were not included (data not shown). In the
analysis sample, the mean number of BMDs per woman was
9 and the median was 10 (of a maximum possible 10).
Figures 1 and 2 illustrate the longitudinal loess plots of mean
LS and FN BMD as a function of number of months before or after
the FMP (based on the date each BMDwas obtained and the FMP
date). At both bone sites, there appeared to be no decline in BMD
before 1 year before the FMP, bone loss began 1 year before the
FMP, and decelerated, but did not cease, 2 years after the FMP.
The loess plots also showed that trajectories were essentially
linear within each of these three time intervals. To construct
piecewise regressions, we therefore divided the BMD trajectories
into three linear segments in relation to FMP date. The first
segment consisted of the period from 5 years before the FMP to
1 year before the FMP, termed pretransmenopause. The second
segment spanned the interval from 1 year before the FMP
through 2 years after the FMP, termed transmenopause. The final
segment started 2 years after the FMP and ended 5 years after
the FMP, termed postmenopause. (See Materials and Methods
for tests of adequacy of breakpoint [knot] selections.)
Table 1 summarizes the results of the piecewise linear models
that quantified LS BMD loss in each of the three segments, ie,
pretransmenopause, transmenopause, and postmenopause.
White women with average baseline LS BMD of 1.066 gm/cm2,
average baseline BMI of 27.1 kg/m2, and average age at FMP of
51.6 years are the reference sample. The slopes shown for
the white referent (row 1) are absolute slopes, reflecting the
average rate of change in BMD during each segment. White
transmenopausal change in LS BMD was 2.46% per year and
postmenopausal change was1.04% annually; summed 10-year
change was 10.6%.
Also shown in Table 1 are the associations of BMI (per kg/m2),
race/ethnicity, and age at FMP with slopes in each of the
segments. The figures shown in rows 2 to 6 are relative slopes;
when added to the slope values of the white referent, the figures
in rows 2 to 6 of the table yield the average slopes in womenwho
Fig. 1. The longitudinal trajectory of baseline-normalized lumbar spine
bone mineral density (BMD) values in relation to the amount of time
before (negative numbers) or after (positive numbers) the final menstrual
period (FMP [time zero]). This loess plot illustrates no measurable decline
in lumbar spine BMD during the interval between 5 years and 1 year
before the FMP, BMD loss starting 1 year before the FMP that continued
for 2 years after the FMP, and a deceleration, but not cessation, of BMD
loss 2 years after the FMP.
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have that alternate characteristic. For example, higher BMI was
associated with less bone loss in all segments of the curve,
indicated by positive coefficients in pretransmenopause,
transmenopause, and postmenopause (þ0.008%, þ0.063%,
þ0.018%, respectively, per BMI unit). These positive coefficients
do not indicate that women with greater BMI gained bone.
Rather, they show that average rates of bone loss (given in row 1
of Table 1) were lessened by these amounts in women with a BMI
one unit higher than the sample average. Whites with BMI values
one standard deviation (7.5 kg/m2) above average would still
lose bone—a 10-year total of 8.50%—but a statistically smaller
amount than the sample average 10-year loss of 10.6%. Being
African American was associated with less transmenopausal
spinal BMD loss (2.19% per year) and a 10-year BMD change of
9.6%, borderline statistically significantly lower than the
Caucasian 10-year rate. During the pretransmenopausal
segment, Chinese women lost LS BMD at a faster rate than
White and Chinese 10-year LS BMD loss was 12.6%.
Results for FN BMD are presented in Table 2. White women
with sample-average BMI, age at FMP, and baseline FN BMD
(0.832 gm/cm2) lost 1.76% annually during the transmenopausal
interval. They lost 1.15% of FN BMD annually during the
postmenopausal segment. Total 10-year FN loss was 9.1%.
Higher BMI was related to less BMD loss but only during the
transmenopausal interval. The transmenopausal annual FN FMD
loss rate was 1.42% in African Americans, 2.13% in Japanese, and
2.17% in Chinese women. Compared with whites, 10-year FN
BMD loss was greater in Asians and less in African Americans.
Later age at FMP was related to greater loss of both bone sites
during the transmenopause but had no effect on the 10-year
cumulative loss (Tables 1 and 2). Not shown in the tables, women
whose BMI changed during the 10-year period had an ending LS
BMD that was higher by 0.10% per increasing BMI unit (95% CI
Fig. 2. The longitudinal trajectory of baseline-normalized femoral neck
bone mineral density (BMD) values relative to time before or after the
FMP (FMP [time zero]). The span between 5 years and 1 year before the
FMP was characterized by no measurable drop in BMD. This loess plot
illustrates nomeasurable decline in femoral neck BMD during the interval
between 5 years and 1 year before the FMP, BMD loss starting 1 year
before the FMP that continued for 2 years after the FMP, and a
deceleration, but not cessation, of BMD loss 2 years after the FMP.
Table 1. Annual Rates of Change of Lumbar Spine (LS) Bone Mineral Density (BMD) in Relation to the Date of the Final Menstrual Period
(FMP) and the Influence of Body Mass Index (BMI), Race, and Age at the FMP on LS BMD Before, During, and After the FMPa






5 years to 1 year
before FMP
Transmenopause
1 year before to 2 years
after FMP
Postmenopause
2 to 5 years
after FMP
White referentc 0.02% (0.08%, þ0.05%) 2.46% (2.61%, 2.31%) 1.06% (1.21%, 0.91%) 10.6% (11.2%, 10.0%)
Baseline BMI
(per kg/m2)d
þ0.008% (þ0.001%, þ0.015%)þ0.063% (þ0.046, þ0.080%) þ0.018% (þ0.001%, þ0.035%)þ0.28% (þ0.21%, þ0.34%)
Race
Japanese þ0.01% (0.12%, þ0.14%) þ0.20% (0.12%, þ0.52%) 0.04% (0.35%, þ0.28%) þ0.5% (0.7%, þ1.8%)
Chinese 0.14% (0.27%, 0.01%) 0.23% (0.54%, þ0.08%) 0.22% (0.51%, þ0.06%) 2.0% (3.1%, 0.7%)
African American 0.07% (0.18%, þ0.04%) þ0.27% (þ0.02%. þ0.52%) þ0.13% (0.11%, þ0.37%) þ0.9% (0.1%, þ1.9%)
Increasing age
at FMP (years)
þ0.002% (0.020%, þ0.016%) 0.050% (0.091%, 0.009%)þ0.040% (þ0.002%, þ0.079%)0.04% (0.19%, þ0.12%)
aIn addition to the variables listed, themodel is also adjusted for baseline BMD and clinical site. Slope referent values are for white women of average age
at FMP (51.7 years), average baseline BMD (1.066 gms/cm2 at the lumbar spine), and average BMI at baseline (27.1 kg/m2).
bCumulative change during the 10-year period spanning 5 years before to 5 years after the final menstrual period.
cStatistically significant associations are shown in bold italic typeface; significance test of nonzero slopes for white referent; significance test of difference
between slopes in white referent and slopes in the other specified groups.
dSlopes for BMI, race, and age at FMP, when added to the white slope referent values, give the slope in women who have each of these characteristics.
114 GREENDALE ET AL. Journal of Bone and Mineral Research
0.06% to 0.14%) and FN BMD that was higher by 0.35% per unit
increase in BMI (95% CI 0.30% to 0.40%).
It is not possible to know the FMP date prospectively.
Menstrually defined menopause transition categories, based on
bleeding patterns, are therefore used in an attempt to stage the
transition. The inference is that the later the transition stage, the
closer to the FMP. To assess the usefulness of stages based on
bleeding patterns (ie, premenopause, early perimenopause, late
perimenopause, and postmenopause) in gauging where women
are in the bone-loss trajectory, we mapped the menstrually
based stages onto each yearly interval before and after the FMP
(Table 3). During the year before the FMP, when bone loss
Table 2. Annual Rates of Change of Femoral Neck (FN) Bone Mineral Density (BMD) in Relation to the Date of the Final Menstrual Period
(FMP) and the Influence of Body Mass Index (BMI), Race and Age at the FMP on FN BMD Before, During, and After the FMPa






5 years to 1 year
before FMP
Transmenopause
1 year before to 2 years
after FMP
Postmenopause
2 to 5 years
after FMP
White referentc 0.06% (0.13%, þ0.01%) 1.76% (1.92%, 1.61%) 1.12% (1.32%, 1.04%) 9.1% (9.7%, 8.5%)
Baseline BMI
(per kg/m2)d
þ0.001% (0.008%, þ0.010%)þ0.025% (þ0.006%, þ0.044%)þ0.001% (0.015%, þ0.017%)þ0.08% (þ0.01%, þ0.16%)
Race
Japanese 0.05% (0.20%, þ0.11%) 0.37% (0.70%, 0.04%) 0.12% (0.41%, þ0.17%) 1.7% (2.9%, 0.38%)
Chinese 0.06% (0.22%, þ0.09%) 0.41% (0.73%, 0.09%) þ0.11% (0.15%, þ0.37%) 1.2% (2.4%, þ0.0%)
African American 0.02% (0.14%, þ0.11%) þ0.34% (þ0.08%, þ0.61%) þ0.03% (0.19%, þ0.26%) þ1.1% (þ0.1%, þ2.1%)
Increasing age at
FMP (years)
þ0.013% (0.008%, þ0.035%)0.055% (0.098%, 0.013%)þ0.000% (0.035%, þ0.035%) 0.11% (0.27%, þ0.05%)
aIn addition to the variables listed, the model is also adjusted for baseline femoral neck BMD and clinical site. Slope referent values are for white women
of average age at FMP (51.7 years), average baseline BMD (0.832 gms/cm2 at the femoral neck), and average BMI at baseline (27.1 kg/m2).
bCumulative change during the 10-year period spanning 5 years before to 5 years after the final menstrual period.
cStatistically significant associations are shown in bold italic typeface; significance test of nonzero slopes for white referent; significance test of difference
between slopes in white referent and slopes in the other specified groups.
dSlopes for BMI, race, and age at FMP, when added to the white slope referent values, give the slope in women who have each of these characteristics.
Table 3. Number of Observations Made in Each 12-Month Period Before and After the Final Menstrual Period (FMP) and the Relation






















60 to 49 485 1.07 0.83 178 (36.8) 304 (62.8) 2 (0.4) 0 (0.0)
48 to 37 563 1.07 0.83 155 (27.6) 396 (70.5) 11 (1.9) 0 (0.0)
36 to 25 618 1.07 0.83 116 (18.8) 481 (77.8) 21 (3.4) 0 (0.0)
24 to 13 697 1.07 0.83 64 (9.2) 552 (79.7) 77 (11.1) 0 (0.0)
12 to FMP 742 1.05 0.82 32 (4.3) 503 (68.0) 205 (27.7) 0 (0.0)
FMP to þ12 871 1.03 0.82 8 (0.9) 266 (30.5) 535 (61.4) 62 (7.1)
13 to 24 703 1.00 0.79 0 (0.0) 0 (0.0) 0 (0.0) 703 (100)
25 to 36 602 0.99 0.78 0 (0.0) 0 (0.0) 0 (0.0) 602 (100)
37 to 48 456 0.97 0.77 0 (0.0) 0 (0.0) 0 (0.0) 456 (100)
49 to 60 372 0.97 0.77 0 (0.0) 0 (0.0) 0 (0.0) 372 (100)
aMenstrually defined menopause stages are based on self-reported bleeding patterns obtained by annual interview. Menopause transition stage
categories are: premenopausal, characterized by regular menses; early perimenopausal, defined as menses within the last 3 months but less predictable
compared with participant’s prior pattern; late perimenopausal, defined as having had at least 3 months, but less than 12 consecutive months, of
amenorrhea; and postmenopausal, characterized by having experienced 12 or more months without menses.
bThe number of months either before or after the FMP that each on-study BMDwas obtained. In this article, based on patterns of BMD loss in relation to
the FMP, the following terminology is used: The time interval between 5 years and 1 year before the FMP is called pretransmenopause. The interval
spanning 1 year before to 2 years after the FMP is termed the transmenopause. The interval between 2 and 5 years after the FMP is called the
postmenopause. These FMP-based categories are distinct from the menstrually based menopause transition category definitions given in footnote a.
cCrude mean values of lumbar spine or femoral neck BMD in each 1-year interval before or after the FMP.
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accelerated, 68% of participants who were observed were still
classified as early perimenopausal based on bleeding patterns.
Even in the year after the FMP, 30% of observations were in
women still classified as early perimenopausal according to
bleeding patterns. In the year immediately preceding the FMP,
only 30% of BMD observations were in women classified as late
perimenopausal. In the year immediately after the FMP, 62% of
observations were in women classified as late perimenopausal.
Table 3 also provides the crude mean BMD values during each
yearly time interval before and after the FMP. The patterns of
crude mean bone loss correspond closely to the loess plots
(Figs. 1 and 2) and to the piecewise regression models (Tables 1
and 2).
Discussion
In the time span consisting of 5 years before and 5 years after the
FMP, change in BMD was divisible into three linear phases. Bone
loss was not evident during the pretransmenopause, except in
Chinese women, who had a small annual decline. At both the LS
and FN, BMD loss began 1 year before the FMP and slowed 2
years after it, and this transmenopausal loss was greater at the LS
than the FN. Postmenopausal loss rates, defined here as starting
2 years after the FMP, were of similar magnitude at each bone
site and were less than transmenopausal rates of loss.
Cumulative, 10-year LS BMD loss was 10.6%; 7.38% was lost
during the transmenopause. Cumulative, 10-year FN loss was
9.1%; 5.8% was lost during the transmenopause. Base-case
estimates of bone loss rates were based on whites with sample-
average characteristics. Greater BMI and African American
heritage were related to slower loss rates, whereas the opposite
was true of Japanese and Chinese ancestry.
The trajectory of menopause-related bone change is best
captured by anchoring it to the FMP, as was done a decade ago
in an 8-year longitudinal study of 75 initially premenopausal
white women, in which an exponential curve was used to
characterize BMD loss relative to FMP date.(4) In that study, LS
and FN bone loss accelerated 2 years before the FMP. Loss
continued for 3 to 4 years after the FMP at the LS and for about
1.5 years after the FMP at the FN. These estimated times of onset
and offset of transmenopausal loss ostensibly differ from
SWAN’s, but the former study did not report parametric testing
of the acceleration and deceleration points. Because of
differences in statistical modeling used in the former and the
current study, it is not feasible to compare their estimates of
transmenopausal bone loss. However, in the former study,
cumulative BMD losses in the period spanning 4 years before and
4 years after the FMP were 10% at the spine and 9.5% at the hip,
similar to SWAN’s 10-year cumulative losses. Using a combina-
tion of splines and piecewise linear models in a longitudinal
sample of 183 white women, the Michigan Bone Health and
Metabolism Study (MBHMS) found that spine BMD loss
accelerated 2 years before and continued for the 2 years after
the FMP, whereas the FN BMD acceleration began about 2 to
3 years before the FMP and lasted for 2 years after it.(5)
Differences in estimated acceleration and deceleration times
between MBHMS and SWAN may be in part because of the
smaller sample size in the former study and to the challenge of
estimating velocity changes when these are gradual. In the
MBHMS, spine and hip losses during the interval spanning 1 year
before through 2 years after the FMP were 8.3% and 4.7%,
respectively, concordant with SWAN’s estimates of 7.3% and
5.3% during the same interval at the same bone sites.
Dissimilarities in estimated timing of transmenopausal accelera-
tion and deceleration are less important than similarities among
these three analyses, each of which demonstrate a period of
rapid bone loss in the few years before and after the FMP, more
pronounced at the LS than at the FN.
Transmenopausal BMD loss was greater at the LS than at the
FN, concordant with the higher proportion of trabecular bone at
the former compared with the latter site.(12,13) Riggs, Khosla, and
Melton originally proposed that accelerated, early postmeno-
pausal bone loss affected trabecular bone to a greater degree
than it affected cortical bone and that the subsequent, slower
rate of BMD loss was similar in both bone compartments.(14) The
initial, accelerated phase was ascribed to the loss of a tonic
estrogen effect on bone turnover; the slower phase to estrogen-
deficiency-caused secondary hyperparathyroidism. Newer, CT-
based studies still find a menopausal acceleration of trabecular
bone loss (more pronounced at the lumbar spine than at the
distal tibia or radius) but newly report that trabecular loss begins
in women during their 20 s, whereas tibial and radial cortical
bone losses do not differ from no loss until the MT.(15) We did not
observe bone loss before the transmenopause, likely because of
the lesser sensitivity of DXA compared with CT. The MT (and
concomitant change in estradiol and other factors) appears to
play a major role in onset of cortical bone loss and the
amplification of trabecular bone loss in midlife women.(16,17)
Body mass, racial/ethnic origin, and age at FMP were each
associated with bone loss rates, but their effects were manifest
during different segments of the bone loss curves and differed at
the LS and FN sites. Higher baseline BMI was related to slower
rates of LS bone loss during all phases, whereas at the FN it
was associated with slower loss during the transmenopause.
Nonetheless, when cumulated over 10 years, higher BMI
predicted slower bone loss rates at both bone sites, in accord
with most,(1,3,5,18) but not all,(1) longitudinal studies of the MT.
Unlike SWAN’s initial longitudinal findings, we found BMI-
independent, racial/ethnic variation in cumulative10-year bone
loss, mainly because of differences in the rates of transmeno-
pausal bone loss. The discordance between SWAN’s first
longitudinal report and the current one is likely because of a
doubling of the follow-up time and also to our use of the FMP-
date-based primary predictor. Racial/ethnic differences in
cumulative, 10-year bone loss were small, on the order of 1%
to 2%. This absolute difference in amount of bone loss is unlikely
to explain racial/ethnic variations in fracture rates.(6–9) However,
it is intriguing that the racial/ethnic variations in bone loss rates
were almost entirely confined to the transmenopausal segment,
which may have long-term impact on structural integrity
(discussed below). Finally, the effect of increasing age at FMP
on bone loss rate, also isolated to the transmenopause, was quite
small and is not likely to be of clinical or biological significance.
Mapping the menstrually defined MT stages onto the number
of years before or after the FMP (Table 3) pointed out that
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menopause transition stages were not useful clinical signals of
the onset of transmenopausal BMD loss. In the year before the
FMP, 70% of women were classified as early perimenopausal and
only 30% of women were in late perimenopause. This result
appears counter to earlier reports that found minimal BMD loss
during early perimenopause and a dramatic increase in BMD in
late perimenopause—but careful scrutiny will demonstrate that
the findings are indeed compatible and provide complementary
information.(1–3) In the current study, 60% to 80% of the BMD
measures that were made in the years spanning 5 years to 1 year
before the FMP (when no BMD loss occurred) were in early
perimenopausal women; therefore, when one computes average
BMD loss among all women classifed as early perimenopausal, it
is predominantly influenced by this 4-year period of no loss. The
time span during which women were in late perimenopause was
shorter, mainly 1 year before and 1 year after the FMP, consistent
with the higher rates of BMD loss computed for this stage when
menstrually based classifications are used. But only 28% of
women had reached late perimenopause when rapid BMD loss
began, demonstrating that late perimenopause is not a
clinically sensitive indicator that substantive BMD loss is starting.
Finally, it may seem counterintuitive that 30% of participants were
classified as early perimenopausal the year after their FMP
occurred. However, the FMP date can only be known in retrospect;
these are women who have ‘‘more abrupt’’ natural menopause—
ie, who transition directly from irregular menses to no menses
without having had a menstrual gap of at least 3 months.
Does accelerated BMD loss during the transmenopause have
clinical implications? On average, the absolute quantity of BMD
lost during the 3-year transmenopausal phase, 7.4% at the LS and
5.3% at the FN, is unlikely to result in a BMD value sufficiently low
to meet even the most conservative treatment recommenda-
tions. For example, a white woman with a baseline FN BMD at the
5th percentile for SWAN whites, 0.69 g/cm2 (a T-score 1.4),
would have a femoral neck BMD of0.64 g/cm2 2 years after the
FMP (a T-score of1.8). But absolute decline in BMDmay be less
critical than the rapid bone turnover that it signals. Rapid
turnover may damage skeletal structural integrity, through loss
of trabecular elements, diminished trabecular connectivity,
weakened trabeculae, and erosion of the endosteal cortex.(19)
During the MT, histomorphometry and 3Dmicro CT demonstrate
declines in trabecular number, enlargement of trabecular
spacing, and conversion of trabecular plates to rods, in direct
correspondence with increases in activation frequency.(19,20)
Concern about irreparable architectural damage to bone has led
some to advocate for short-term antiresorptive therapy during
the MT in an attempt to prevent such damage.(21) Although we
concur that the major import of transmenopausal accelerated
bone loss may be its threat to microarchitecture, we do not
believe that the currently available data are sufficient to
recommend treatment. Rather, further characterization of this
phenomenon is essential.
Strengths of this analysis include its large sample size, number
of FMPs observed, ability to compare patterns of bone loss
directly among women from four racial/ethnic groups, and
multiple longitudinal measurements. The analysis method,
linking patterns of bone loss to the FMP, newly points out the
incapacity of menstrually defined MT stages to signal the onset
of transmenopausal BMD loss. Study limitations include some
uncertainty in the timing of the acceleration and deceleration of
BMD loss, especially the latter, which was much less distinct.
Ten-year loss rates were computed to militate against this
uncertainty in knot placement. Because SWAN enrolled women
who were in their mid-40s, we cannot capture the period of time
earlier than 5 years before the FMP; additional follow-up will
permit us to extend observations beyond 5 years post-FMP. Non-
white sample sizes were large enough to detect racial/ethnic
differences in BMD trajectories but not large enough for us to
test for interactions within race. Two sites changed Hologic bone
densitometer models; however, in vivo cross-calibration proto-
cols were done.
In conclusion, this analysis confirms that there is a period of
rapid BMD loss that brackets the FMP and commences about
1 year before it and newly reports that transmenopausal BMD
loss is independently influenced by ethnicity and body mass.
Future work should determine whether rapid transmenopausal
bone loss permanently damages bonemicroarchitecture or bone
strength. Clinically useful signals that presage the onset of
transmenopausal BMD loss also require elucidation.
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